U.S. Senate Committee on Judiciary

11/17/2026 | Press release | Distributed by Public on 11/17/2026 10:51

Grassley Opens Judiciary Hearing Examining Avenues to Make Prescription Drugs More Affordable

Published: 11.17.2026

Grassley Opens Judiciary Hearing Examining Avenues to Make Prescription Drugs More Affordable

Prepared Opening Statement by Senator Chuck Grassley of Iowa

Chairman, Senate Judiciary Committee

"Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs"

Tuesday, November 17, 2026

I'd like to welcome everyone to this hearing examining how competition and transparency can lower prescription drug costs.

Today, we're examining questions that matter to every family. Why do prescription drugs cost so much? How do we make them affordable?

Needless to say, the prescription drug supply chain is complicated.

Manufacturers set list prices. Wholesalers and distributors move products. Pharmacy benefit managers set prices, build formularies, process claims and create pharmacy networks.

Insurers and employers design benefits. Pharmacies fill the prescriptions. Each one of these participants affects the final cost.

However, when the transactions are hidden behind confidential contracts, rebates, fees and payments to affiliated companies, patients and consumers have a hard time following the money.

When companies are allowed to engage in anticompetitive and abusive tactics, drug prices remain high for patients.

Last year, the Senate Judiciary Committee advanced six bipartisan bills that address the high cost of prescription drugs and the abusive practices that keep prices too high for too many American families.

They'll help make medications more affordable for the patient.

These bills address anticompetitive tactics in the pharmaceutical supply chain, including opaque pharmacy benefit managers' (PBMs) practices, product hopping, patent games, sham citizen petitions, pay-for-delay deals and the need to strengthen collaboration in the drug patent process between the FDA and Patent Office.

I'm glad the Senate unanimously passed the Affordable Prescriptions for Patients Act in July.

It's time for the Senate to pass the five other bills.

Last year, the Senate Judiciary Committee held a hearing focused specifically on PBMs. We learned that these entities originally existed to process pharmacy claims. Then, they began negotiating prices and managing drug benefits.

In recent years, PBMs' role has continued to evolve. They now exercise significant power over what medications patients can access, how much the patient will pay, how the pharmacy gets paid and much more.

My two-year bipartisan investigation into insulin price gouging, cited by the FTC, found that PBMs encourage drug makers to spike a drug's list price in order to offer a greater rebate. This, in turn, allows manufacturers to secure priority placement on covered meds - all at the expense of patients.

For years, I've pressed the FTC to study PBMs, and their impact on competition and drug costs.

I'm glad that the FTC listened to me and began their study into PBMs in 2022.

While the FTC's two interim staff reports are helpful, I'm eager to get their full report with legislative recommendations. Last month, I asked the FTC for an update on when Congress will see the report.

I also appreciate that the FTC has issued two proposed consent orders with major PBMs. The enforcement of those settlements will need to be monitored to ensure they benefit patients.

While a report on PBMs is crucial, we can address some anti-competitive behavior today. In February, Congress took some action on PBM reform in Medicare Part D and the private insurance market.

I'm glad the Department of Labor implemented its regulation last month. I look forward to the Centers for Medicare and Medicaid Services completing its regulatory work next year. I'm watching both regulations closely to ensure they help patients and lower drug costs.

These are good first steps, but more PBM reform is needed. I'm on the record calling for more transparency and accountability of PBMs.

The PBM industry may try to argue that they've changed their ways and they're more accountable, but I disagree.

PBMs are still too opaque and powerful, while patients, pharmacies and taxpayers are being hurt by these powerful drug middlemen.

The efforts to lower prescription drug costs are bipartisan.

The Senate should also consider the Drug-price Transparency for Consumers Act. This bill is a priority of Senator Durbin and mine. If a drug company can advertise a prescription drug directly to the public, it should disclose the product's price to the public too.

Sunlight gives patients information to ask better questions about price and lower-cost alternatives before they purchase at the pharmacy counter.

I appreciate President Trump's commitment to lowering drug costs, holding foreign countries accountable for benefiting from American medical innovation and protecting rural health care through price transparency and the $50 billion Rural Health Transformation Fund.

The Trump administration's work to root out fraud, waste and abuse in health care programs is also ensuring resources are going to those who most need them while protecting taxpayers.

Today's hearing is about the prescription drug supply chain as a whole. The entire prescription drug supply chain needs to be put under a magnifying glass.

Accountability must follow the decision maker.

No participant can hide behind the complexity of the system or conveniently shift responsibility.

I appreciate Senator Durbin's partnership in holding this hearing.

Today, we'll hear testimony from a patient advocacy organization, the co-founder of a transparent cost-plus pharmacy, the Iowa Pharmacy Association, a health economist and a CEO of Illinois health clinics.

They bring different perspectives. I thank each of the witnesses for being here, and I look forward to the discussion.

-30-

  • Print
  • Email
  • Share
  • Post
U.S. Senate Committee on Judiciary published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 16:51 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]